The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
NCT ID: NCT07214675
Last Updated: 2025-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
80 participants
INTERVENTIONAL
2026-03-31
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)
NCT01775488
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
NCT01896973
To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.
NCT02962674
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
NCT06849258
A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
NCT00465101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HistoSonics Edison System
HistoSonics Edison System
The HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HistoSonics Edison System
The HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
3. Subject is diagnosed with BPH.
4. Subject has a Body Mass Index (BMI) \< 27.
5. Subject has an I-PSS ≥ 15.
6. Subject has a prostate volume \> 30 mL and ≤ 150 mL.
7. Subject has a Qmax ≤ 15 mL/s with a voided volume of ≥ 125 mL during a uroflow test.
8. Subject accepts the potential loss of ejaculatory function.
9. Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)
10. Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.
11. Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.
Exclusion Criteria
2. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
3. Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.
4. Subject has an estimated glomerular filtration rate (eGFR) ≤ 50 mL/min, ≤ 14 days prior to the planned index procedure date.
5. Subject has uncorrectable coagulopathy.
6. Subject has an International Normalized Ratio (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.
7. Subject has had a prostatectomy.
8. Subject has acute prostatitis.
9. Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.
10. Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.
11. Subject has bladder stones.
12. Subject is catheter dependent or has a history of intermittent self-catheterization.
13. Presence of prostatic calcifications in the planned treatment volume (PTV).
14. Presence of permanent radioactive implants in the rectal wall.
15. Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.
16. Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
17. Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
18. Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
19. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
20. In the investigator's opinion, histotripsy is not a treatment option for the subject.
21. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
22. Subject's prostate is not treatable by the System's working ranges (refer to User Guide).
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HistoSonics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSP5895
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.